Nuechterlein Carole 4
4 · Aligos Therapeutics, Inc. · Filed Oct 27, 2023
Insider Transaction Report
Form 4
Nuechterlein Carole
Director
Transactions
- Purchase
Common Stock
2023-10-25$0.76/sh+7,933,601$6,004,149→ 11,025,941 total(indirect: See footnote) - Purchase
Warrant (Right to Buy)
2023-10-25$0.13/sh+3,966,800$495,850→ 3,966,800 total(indirect: See footnote)Exercise: $0.76From: 2023-10-25Exp: 2030-10-25→ Common Stock (3,966,800 underlying)
Footnotes (1)
- [F1]Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4.